Notably, we also found that several cancer-related mutation sites in RhoA, such as A3, R5, and E5453–55, are located at the interface with the TRPV4 ARD (Fig. 5c, d), providing evidence for an interplay between TRPV4 and RhoA in cancer25,26,56, although these RhoA mutations may also impact effector binding more broadly. Here, TRPV4 is linked to cancer.